LEXX (Lexaria Bioscience) Beta: 0.3696 (As of Jun. 25, 2026)


LEXX Lexaria Bioscience Corp LEXX
28 GF Score
Price $0.54
GF Value $0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lexaria Bioscience Beta?

Lexaria Bioscience LEXX -3.61% 28 Beta is 0.3696 as of Jun. 25, 2026. GuruFocus rates LEXX with a GF Score™ of 28/100 and a GF Value™ of $0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Lexaria Bioscience's Beta is 0.3696.


Lexaria Bioscience  (NAS:LEXX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lexaria Bioscience Beta Related Terms


Lexaria Bioscience Beta Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Beta Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.83 0.50 0.66 0.80 1.49

Lexaria Bioscience Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.57 1.49 1.52 1.32

LEXX vs MBRX, ICU, INTI: Beta Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Beta distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Beta falls into.


LEXX
28GF Score
Lexaria Bioscience Corp LEXX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3696 mean?
Lexaria Bioscience (LEXX) has a Beta of 0.3696 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Beta too high?
Lexaria Bioscience's current Beta is 0.3696. Overall, Lexaria Bioscience has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Beta compare to MBRX and ICU?
Lexaria Bioscience's Beta of 0.3696 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lexaria Bioscience and its competitors. Lexaria Bioscience's current Beta is 0.3696. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.75, compared to a current price of $0.54 — trading 27.7% below its estimated fair value. The current Beta is 0.3696. Lexaria Bioscience's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Beta is 0.3696 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75. GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.

Key valuation signals for LEXX:

  • Beta: 0.3696
  • GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score

Get the complete analysis for LEXX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.75
GF Value